AAA
VRTX icon

Affinity Asset Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Affinity Asset Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,000
Closed -$2.2M – 83
2020
Q4 		$2.36M Buy
+10,000
New +$2.29M 1.25% 22

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Affinity Asset Advisors's VRTX Position: Q1 2021 in Review

Affinity Asset Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q1 2021, closing a stake of 10,000 shares — an estimated $2.2M sold.

Affinity Asset Advisors first reported a position in VRTX in Q4 2020 and held it in 1 quarter. The position peaked at $2.36M in Q4 2020. 999 funds tracked by Wall St. Rank hold VRTX as of Q1 2021.

  • Affinity Asset Advisors reported no remaining Vertex Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Affinity Asset Advisors sold 10,000 Vertex Pharmaceuticals shares in Q1 2021, an estimated $2.2M.
  • Affinity Asset Advisors first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Affinity Asset Advisors's Vertex Pharmaceuticals position peaked at $2.36M in Q4 2020.
  • 999 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2021.

Based on Affinity Asset Advisors's 13F filing for Q1 2021, filed 14 May 2021.